Congenital diaphragmatic hernia (CDH) has an incidence of 1 in 3,000 births and a high mortality rate (33%-58%). Multifactorial inheritance, teratogenic agents, and genetic abnormalities have all been suggested as possible etiologic factors. To define candidate regions for CDH, we analyzed cytogenetic data collected on 200 CDH cases, of which 7% and 5% showed numerical and structural abnormalities, respectively. This study focused on the most frequent structural anomaly found: a deletion on chromosome 15q. We analyzed material from three of our patients and from four previously published patients with CDH and a 15q deletion. By using array-based comparative genomic hybridization and fluorescent in situ hybridization to determine the boundaries of the deletions and by including data from two individuals with terminal 15q deletions but without CDH, we were able to exclude a substantial portion of the telomeric region from the genetic etiology of this disorder. Moreover, one patient with CDH harbored a small interstitial deletion. Together, these findings allowed us to define a minimal deletion region of ∼5 Mb at chromosome 15q26.1-26.2. The region contains four known genes, of which two-NR2F2 and CHD2-are particularly intriguing gene candidates for CDH.
Congenital diaphragmatic hernia (CDH [MIM 142340])
, a severe, life-threatening, congenital anomaly characterized by variable defect in the diaphragm, pulmonary hypoplasia, and postnatal pulmonary hypertension, is a relatively common anomaly (Torfs et al. 1992; Beresford and Shaw 2000) . CDH can occur as an isolated defect, in combination with multiple congenital anomalies, or as part of a defined syndrome (Fryns et al. 1979; Enns et al. 1998) . Little is known about the etiology of CDH. However, there is increasing evidence for a genetic cause of CDH. Various chromosomal anomalies have been described in CDH, with numerical abnormalities (such as trisomies 13, 18, and 21) as the most common type. Structural chromosomal anomalies, involving almost every chromosome, have been reported (Lurie 2003) . Since 1988, clinical data from all Erasmus Medical Centre patients with CDH have been stored in a database. Cytogenetic data from 200 patients with CDH were available, and 24 patients (12%) showed an abnormality. Fourteen patients (7%) showed a numerical abnormality (trisomy 18 or 21). The remaining 10 patients (5%) had a structural anomaly, and 3 of those patients (1.5%) were shown to have a deletion of part of chromosome 15q. The present study focuses on this subset of patients with CDH and chromosome 15q deletions. Data from four previously published patients with CDH and small chromosome 15q deletions were generously made available to us (table 1) (de Jong et al. 1989; Rosenberg et al. 1992; Chen et al. 1998; Schlembach et al. 2001) . Clinical evaluation of the seven patients revealed a leftsided diaphragmatic hernia of the Bochdalek type, in- 
Figure 1
Array CGH results. trauterine growth retardation (all patients had birth weights !3rd percentile), and multiple other congenital anomalies, such as cardiac and renal abnormalities. In addition to the seven patients with CDH, we analyzed data from two patients with mental retardation and 15q deletions but without CDH manifestation. Genomic DNA was extracted from cultured cells (from patients 1, 2, 3, 4, and 9) or paraffin-embedded tissue (from patients 5 and 6).
To delineate the possible candidate region, arraybased comparative genomic hybridization (array CGH) was performed using the 1-Mb Human BAC Array (Spectral Genomics) in accordance with the manufacturer's instructions. A dye-swap experimental strategy was used as an additional internal control. Fluorescent signals on the arrays were visualized using the ScanArray Express HT scanner. Images were analyzed with Spectral Ware 2 (Spectral Genomics). Results for patients 1, 3, 4, 7, and 8 are shown in figure 1. To further delineate the deleted region and to deter- mine the deletions in patients 4, 5, and 9, ∼110 BAC clones were selected from the University of California Santa Cruz (UCSC) and Ensembl genome browsers to cover the distal part of chromosome 15. Using the appropriate BAC clones, we performed FISH on metaphase chromosomes from patients 1, 3, and 4 ( fig. 2a and 2c-2e). Interphase FISH was performed on nuclei extracted from paraffin-embedded tissues from patients 2, 5, and 6 ( fig. 2b and 2f ; data for patient 5 not shown). Only genomic DNA was available from patients 7 and 8, so the size of the deletion in these patients was determined using only array CGH. FISH slides were analyzed using the Axioplan 2 Imaging microscope (Zeiss), and images were collected using the Isis Software System (Metasystems). Combining FISH and array CGH data, we were able to approximately determine the breakpoints in all patients ( fig. 3) . In patient 1, the interstitial deletion found by array CGH was confirmed and was narrowed to a 6-Mb deletion between BAC clones RP11-79A7 and RP11-616M17. In patient 2, the deletion extended from a region distal to RP11-79A7; in patient 3, it extended from a region distal to RP11-300G22. The proximal breakpoint in patient 4 lies within BAC clone RP11-617F23. In patient 5, the break occurs distal to RP11-300G22. In patient 6, the most distal probe tested that was present on the deleted chromosome 15 was RP11-79A7. The terminal deletion in patient 7 occurs distal to RP11-360F18. The proximal breakpoints of the deletion interval in the two patients without CDH were similarly determined ( fig. 3 ). In the first patient without CDH, who had a ring chromosome 15, the most distal BAC clone tested that was present on the ring chromosome was RP11-120N1. In the second patient without CDH, the most distal BAC clone present was RP11-262P8. Combining all data, we determined the smallest common deletion interval in patients with CDH to be at 15q26.1-26.2 (which we have termed the "CDH region"). This region is ∼5 Mb in size and is bordered by BAC clones RP11-79A7 and RP11-80F4.
CDH is unlike many genetic disorders, for which candidate genes can be determined by using linkage analyses of familial cases, because the vast majority of CDH cases occur de novo. For this type of disorder, the best way to determine which genes are involved is by analyzing a large number of patients for common aberrations by use of different high-resolution genetic methodologies, such as FISH or array CGH. This strategy has already been used successfully to identify genes involved in CHARGE syndrome (MIM 214800) (Vissers et al. 2004) and Cornelia de Lange syndrome (CdLS [MIM 122470]) (Krantz et al. 2004; Tonkin et al. 2004) .
Isolated reports of distal chromosome 15 deletions
Figure 3
Schematic representation of the critical CDH region, with partial ideogram of chromosome 15q. Patients (Pt) 1-7 have CDH; patients 8 and 9 do not have CDH. BAC clones that were tested by array CGH and FISH are listed. The black dots inside boxes indicate that probes have been tested only on the array and not by FISH. The smallest common overlapping deletion interval involved in CDH is denoted by the large red square.
in patients with CDH have been described elsewhere (reviewed by Hengstschlager et al. [2004] and Schlembach et al. [2001] ), suggesting involvement of this region in the pathogenesis of CDH. In the past year, three new cases of CDH have been reported (Biggio et al. 2004; Hengstschlager et al. 2004; Tonks et al. 2004 ). However, detailed molecular cytogenetic analyses of these cases are currently unavailable. To find other possible cases to study, we performed systematic FISH analysis on data from 25 patients with CDH, with the use of BAC clones spanning the CDH region. We identified no additional 15q deletions.
With array CGH and systematic FISH analysis performed on the seven patients with CDH and 15q deletions and the two patients without CDH but with 15q deletions, our study is the first to analyze data from multiple patients with CDH in detail and to refine the chromosome 15q critical CDH region to an ∼5-Mb area within 15q26.1-26.2. In all patients, clinical abnormalities resembled the features described for other patients with a 15q deletion or with related syndromes, such as Fryns syndrome (MIM 229850) (Fryns et al. 1979) . As can be expected, the r(15) patients, with or without CDH, had phenotypes similar to those seen with ring chromosome 15 syndrome (Butler et al. 1988; Rogan et al. 1996) . To our knowledge, CDH has not yet been described as a main feature in ring chromosome 15 syndrome.
In our study, there appears to be a relationship between the number of abnormalities present and the size of the deletion. For example, the first patient, who had the smallest deletion, has few additional congenital defects. All other patients have deletions that are similar in size and have a similar spectrum of anatomical anomalies. In the two patients with an unbalanced translocation, the variation in phenotype could also be due, in part, to the presence of extra material from another chromosome.
The region of the smallest common deletion contains four known genes, none of which have been previously shown to be involved in diaphragm development or diaphragmatic hernia. On the basis of their structure and function, two of these genes are very interesting with respect to a potential relationship with CDH. The first gene, NR2F2 (MIM 107773; also known as "COUP-TFII"), is a member of the steroid/thyroid hormone receptor subfamily and is involved in retinoic acid metabolism (Kimura et al. 2002) . A knockout mouse model of NR2F2 showed that Nr2f2 Ϫ/Ϫ mice are not viable and die at E9 in utero because of arrest of cardiac development (Pereira et al. 1999) . Heterozygous knockout mice have poor viability in the neonatal period and are smaller than wild-type mice. However, the exact cause of death in these mice is not clear. The second interesting gene is the chromodomain helicase 2 gene (CHD2 [MIM 602119]), a member of the SNF2/RAD54 helicase gene family. Recently, mutations in another member of this family (CHD7) have been found to cause CHARGE syndrome (Vissers et al. 2004 ). The third gene in the CDH region is the repulsive guidance molecule gene, RGMA (MIM 607362), which is involved in the guidance of growth cones in developing neurons (Brinks et al. 2004 ). This gene is not known to play a role in diaphragm development, nor has it been described in muscle or lung development. The fourth gene located in the smallest region of overlap is the sialyltransferase 8B gene (SIAT8B [MIM 602546]), which plays a role in the adhesive properties of neural cell adhesion molecules (Angata et al. 1997) .
Haploinsufficiency due to the loss of a copy of one of these genes may be enough to result in a diaphragmatic defect. At the present time, the precise mechanism by which a deletion of or within one of these genes or a related gene mutation causes this developmental defect can only be speculated.
Elsewhere, other genes on chromosome 15q have been suggested as being involved in the pathogenesis of diaphragmatic defects. Biggio et al. (2004) suggested that the myocyte enhancer factor 2A gene, MEF2A (MIM 600660), could be involved in the pathogenesis of diaphragmatic defects. MEF2A maps to 15q26.3 and is involved in the differentiation of muscle cells from their precursors. Some genes involved in vitamin A metabolism-for example, RALDH2 (MIM 603687), which maps to 15q21-have also been implicated in the pathogenesis of CDH (Greer et al. 2003) . Both MEF2A and RALDH2 are located outside our candidate critical CDH region, which limits their possible role in CDH in our subgroup of patients.
In conclusion, we have mapped a potential critical CDH region to 5 Mb at chromosome 15q26.1-26.2, a region that contains four genes, of which two are especially intriguing candidates in the etiology of diaphragmatic defects. Further research is needed to confirm their exact role in CDH and to determine the pathogenic mechanism. As a first step, we are performing FISH and mutation analyses of a large group of patients with CDH who have normal karyotypes. In the future, prenatal screening for 15q abnormalities when a diaphragmatic hernia is detected could give better clues for predicting the outcome and could provide more information for genetic counseling.
